Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | PTPRA | P18433 | 1/20 | 0.67 |
| ▸ | PTPRB | P23467 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | SUMO2 | P61956 | 1/20 | 0.59 |
| ▸ | SUMO1 | P63165 | 1/20 | 0.59 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.59 |
| ▸ | SENP3 | Q9H4L4 | 1/20 | 0.59 |
| ▸ | SENP2 | Q9HC62 | 1/20 | 0.59 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.55 |
| ▸ | THRB | P10828 | 3/20 | 0.54 |
| ▸ | ENPP2 | Q13822 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8528180 | 1.00 | CYP1A2 (0.70) | CYP1A2CYP2C9HIF1ATSHRPTPRA | |
| SCHEMBL30742587 | 1.00 | CYP1A2 (0.70) | CYP1A2CYP2C9HIF1ATSHRPTPRA | |
| SCHEMBL28547156 | 0.99 | CYP1A2 (0.68) | CYP1A2CYP2C9HIF1ATSHRPTPRA | |
| SCHEMBL15424240 | 0.94 | HIF1A (0.76) | CYP1A2CYP2C9HIF1ATSHRPTPRA | |
| SCHEMBL15424214 | 0.91 | CYP1A2 (0.68) | CYP1A2CYP2C9HIF1ATSHRPTPRA | |
| SCHEMBL5160460 | 0.90 | CYP1A2 (0.71) | CYP1A2CYP2C9HIF1ATSHRPTPRA | |
| SCHEMBL12955458 | 0.90 | CYP1A2 (0.71) | CYP1A2CYP2C9HIF1ATSHRPTPRA | |
| SCHEMBL1435843 | 0.89 | CYP1A2 (0.69) | CYP1A2CYP2C9HIF1ATSHRPTPRA | |
| SCHEMBL1435839 | 0.89 | CYP1A2 (0.69) | CYP1A2CYP2C9HIF1ATSHRPTPRA | |
| SCHEMBL19695889 | 0.83 | CYP1A2 (0.60) | CYP1A2CYP2C9HIF1ATSHRPTPRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050147673-A1 | Directly compressible sustained release formulation containing microcrystalline cellulose | J. RETTENMAIER & SOEHNE GMBH + CO. KG (DE) | 2005-07-07 | — | — | US | claimed |
| US-6106865-A | MIXTURE OF MICROCRYSTALLINE CELLULOSE, COMPRESSIBILITY, SILICA AND SURFACTANTS | EDWARD MENDELL CO., INC. (US) | 2000-08-22 | — | — | US | claimed |
| US-5858412-A | FORMING AQUEOUS SLURRY OF MICROCRYSTALLINE CELLULOSE AND COMPRESSIBILITY AUGMENTING AGENT, DRYING TO FORM AGGLOMERATED PARTICLES, ADDING ACTIVE AGENT, INCORPORATING SUSTAINED-RELEASE CARRIER | EDWARD MENDELL CO., INC. (US) | 1999-01-12 | — | — | US | claimed |
| US-5430074-A | Methacrylic resins | JENERIC/PENTRON, INCORPORATED (US) | 1995-07-04 | — | — | US | claimed |
| US-20250255843-A1 | COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF | Nature's Fusions, LLC | 2025-08-14 | — | — | US | disclosed |
| US-20240207209-A1 | Threonate Compounds and Methods of Use Thereof | NEUROCENTRIA, INC. | 2024-06-27 | — | — | US | disclosed |
| WO-2024026124-A1 | COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF | PETERSON MATTHEW (US) | 2024-02-01 | — | — | WO | disclosed |
| US-20230355556-A1 | Threonate Compounds and Methods of Use Thereof | NEUROCENTRIA, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230116091-A1 | Threonate Compounds and Methods of Use Thereof | NEUROCENTRIA, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20220249412-A1 | Threonate Compounds and Methods of Use Thereof | NEUROCENTRIA, INC. | 2022-08-11 | — | — | US | disclosed |
| US-11298330-B2 | Magnesium compositions and methods of use | NEUROCENTRIA, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| US-20210393561-A1 | Threonate Compounds and Methods of Use Thereof | NEUROCENTRIA, INC. | 2021-12-23 | — | — | US | disclosed |
| US-20030099702-A1 | Pharmaceutical excipient having improved compressibility | PENWEST PHARMACEUTICALS CO. | 2003-05-29 | — | — | US | disclosed |
| EP-1289381-A2 | LOW-STAINING ORANGE FOOD COLORING COMPOSITION | PepsiCo, Inc. (US) | 2003-03-12 | — | — | EP | disclosed |
| US-20020182259-A1 | Process for preparing a directly compressible solid dosage form containing microcrystalline cellulose | J. RETTENMAIER & SOEHNE GMBH + CO. KG (DE) | 2002-12-05 | — | — | US | disclosed |
| US-20020122851-A1 | Low-staining orange food coloring composition | PEPSICO, INC. | 2002-09-05 | — | — | US | disclosed |
| US-6395303-B1 | Process for preparing a directly compressible solid dosage form containing microcrystalline cellulose | EDWARD MENDELL CO., INC. | 2002-05-28 | — | — | US | disclosed |
| WO-2001091585-A2 | LOW-STAINING ORANGE FOOD COLORING COMPOSITION | PEPSICO, INC. (US) | 2001-12-06 | — | — | WO | disclosed |
| US-6106865-A | MIXTURE OF MICROCRYSTALLINE CELLULOSE, COMPRESSIBILITY, SILICA AND SURFACTANTS | EDWARD MENDELL CO., INC. (US) | 2000-08-22 | — | — | US | disclosed |
| US-5430074-A | Methacrylic resins | JENERIC/PENTRON, INCORPORATED (US) | 1995-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210393561-A1 | Threonate Compounds and Methods of Use Thereof | SLC18A2, SLC1A2, SLC18A3 | CYP1A2 4821/4885CYP2C9 4796/4885HIF1A 3938/4885 |
| US-20240207209-A1 | Threonate Compounds and Methods of Use Thereof | SLC18A2, SLC1A2, SLC18A3 | CYP1A2 4821/4885CYP2C9 4796/4885HIF1A 3938/4885 |
| US-20230116091-A1 | Threonate Compounds and Methods of Use Thereof | SLC18A2, SLC1A2, SLC18A3 | CYP1A2 4821/4885CYP2C9 4796/4885HIF1A 3938/4885 |
| US-20250255843-A1 | COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF | AHCY, MGMT, CBS | CYP1A2 1349/4885CYP2C9 307/4885HIF1A 4468/4885 |
| US-20220249412-A1 | Threonate Compounds and Methods of Use Thereof | SLC18A2, SLC1A2, SLC18A3 | CYP1A2 4821/4885CYP2C9 4796/4885HIF1A 3938/4885 |
| US-11298330-B2 | Magnesium compositions and methods of use | SLC5A6, SLC6A6, SLC6A5 | CYP1A2 520/4885CYP2C9 367/4885HIF1A 4640/4885 |
| US-20230355556-A1 | Threonate Compounds and Methods of Use Thereof | SLC18A2, SLC1A2, SLC18A3 | CYP1A2 4821/4885CYP2C9 4796/4885HIF1A 3938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.